Global Single-Use Biopsy Device Market Strategic Research Report

Scope of the Report

The global Single-Use Biopsy Device market size is predicted to grow from US$ 1,537 million in 2025 to US$ 2,976 million in 2032; it is expected to grow at a CAGR of 9.9% from 2026 to 2032.

Single-use biopsy devices are disposable biopsy instruments and consumable sets intended for one patient and one procedure, including single-use biopsy needles (FNA/CNB), disposable components for vacuum-assisted biopsy systems, endoscopic/bronchoscopic disposable biopsy forceps and sampling tools, and disposable punch or core biopsy instruments for skin and soft tissue. Their value proposition is to replace the complexity of cleaning, disinfection/sterilization, and reuse governance with a sterile, ready-to-use workflow—reducing cross-contamination risk and reprocessing failures while improving throughput and specimen consistency. As image-guided biopsy, molecular testing, and precision diagnostics raise expectations for specimen integrity and traceability, single-use adoption is increasingly tied to hospital quality systems, compliance, and pathway standardization. In 2025, global Single-use biopsy devices production reached approximately 52.37 Million Units and price is about 30 USD/Unit.The average gross profit margin of this product is 45%.

Adoption is propelled by a dual mandate: patient safety and workflow certainty. Infection prevention and quality governance emphasize that single-use devices are intended for one patient and one procedure, with disposal after use—making disposable biopsy workflows an intuitive way to reduce cross-contamination risk and simplify reprocessing burden and staff training. In parallel, the regulatory landscape around reuse and reprocessing has become more systematized, prompting healthcare facilities to reassess the “true total cost” of reuse under compliance—strengthening the strategic appeal of disposable solutions.

The competitive bar is shifting from “disposable by design” to “diagnostic-grade performance at scale.” Across anatomies and image-guided pathways, clinicians demand consistent tactile control, needle-tip geometry, tissue yield, specimen integrity, and complication management—where engineering reproducibility becomes the decisive differentiator. Meanwhile, reusable instruments and FDA-regulated reprocessing of certain single-use devices remain cost strategies in some facilities, requiring nuanced trade-offs among compliance, quality, and economics; regulators also expect validated reprocessing instructions and clear labeling where applicable, raising the importance of auditable documentation and verification systems.

Demand is moving from “consumable purchasing” toward pathway-level kits. Image-guided biopsy and multidisciplinary care favor standardized sampling workflows, pushing providers to prefer disposable systems that integrate smoothly with imaging platforms and downstream pathology/molecular lab requirements. As outpatient and day-case models expand, throughput, predictability, and supply assurance rise in priority—where single-use solutions gain advantage by removing reprocessing steps. For department leaders, traceability, training simplicity, and quality-control governance are becoming procurement criteria as influential as unit price.

Upstream value is defined by a combined capability in medical-grade materials, precision manufacturing, and sterile barrier systems. Typical inputs include stainless steel or nitinol cannulas and cutting components, engineered plastics/polymers for handles and sheaths, micro-springs and actuation mechanisms, lubricious/surface treatments, and sterile packaging materials (blister packs, medical paper, Tyvek) with validated sterilization services. Because disposable biopsy devices depend on batch-to-batch consistency and sterility assurance, supply chains must deliver rigorous traceability, sterilization validation, and labeling compliance; in the EU, UDI-driven traceability further elevates labeling and supply-chain digitalization as core capabilities.

Key Questions Addressed in this Report

What is the 10-year outlook for the global Single-Use Biopsy Device market?

What factors are driving Single-Use Biopsy Device market growth, globally and by region?

Which technologies are poised for the fastest growth by market and region?

How do Single-Use Biopsy Device market opportunities vary by end market size?

How does Single-Use Biopsy Device break out by Type, by Application?

This report presents a comprehensive overview of the global Single-Use Biopsy Device market, covering market size and forecast, segmentation by product type and application, competitive landscape, leading players and regional and country-level outlook.

Segment by Type

• Disposable Biopsy Needle
• Disposable Biopsy Forceps
• Disposable Puncture Sampler
• Other

Segment by Target Anatomy

• Breast
• Lung / Bronchoscopy
• GI / pancreatobiliary
• Other

Segment by Specimen Type

• Cytology
• Histology Core/Tissue
• Other

Segment by Application

• Hospital
• ASCs
• Other

Who Can Use This Report?

This report is written for decision-makers who need a clear, data-backed view of the global Single-Use Biopsy Device market:

• Manufacturers, suppliers and solution providers benchmarking their position and planning product, capacity and go-to-market strategy
• Distributors, channel partners and end users in Hospital, ASCs, Other evaluating demand and sourcing options
• Investors, financial analysts and consultants assessing growth opportunities, competitive dynamics and M&A potential
• Government agencies, industry associations and research institutions tracking industry developments and policy impact